Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stroke-fighting drug offers potential treatment for traumatic brain injury

08.10.2014

The only drug currently approved for treatment of stroke's crippling effects shows promise, when administered as a nasal spray, to help heal similar damage in less severe forms of traumatic brain injury.

In the first examination of its kind, researchers Ye Xiong, Ph.D, Zhongwu Liu, Ph.D., and Michael Chopp, Ph.D., Scientific Director of the Henry Ford Neuroscience Institute, found in animal studies that the brain's limited ability to repair itself after trauma can be enhanced when treated with the drug tPA, or tissue plasminogen activator.

"Using this novel procedure in our earlier stroke studies, we found significant improvement in neurological function," said Michael Chopp, Ph.D., scientific director of the Henry Ford Neuroscience Institute. "So we essentially repeated the experiment on lab rats with subacute traumatic brain injury, and with similar remarkable results.

"As in stroke treated intra-nasally with tPA, our subjects showed greatly improved functional outcome and rewiring of the cortical spinal tract."

The new study was recently published in the Public Library of Science's peer-reviewed online journal PLOS ONE.

Commonly called a "clot-buster," tPA is the only FDA-approved treatment for acute ischemic stroke.

Acute ischemic stroke occurs when oxygen-rich blood flow to the brain is blocked by a clot. Resulting damage to oxygen-starved brain cells can lead to physical impairment, mental disabilities and sometimes death.

In the case of traumatic brain injury, damage is due to a violent blow or other external assault.

It has been known for some time that stroke damage can be reduced if tPA is given intravenously within 4.5 hours. But tPA administered through the bloodstream also has potentially harmful side effects, including swelling of the brain and hemorrhage.

More recently, however, Henry Ford researchers found that the effective treatment window could be extended to as much as two weeks for lab rats dosed with tPA in a nasal spray, while avoiding the harmful side effects of intravenous injection.

Although scientists do not yet fully understand how it works, earlier research has shown that drugs administered through the nose directly target both the brain and spinal cord.

Traumatic brain injury is a leading cause of death and disability throughout the world. While the new Henry Ford study offers hope of a drug treatment, so far no effective pharmacological therapy is available.

These most recent findings suggest that tPA has the potential to be a noninvasive treatment for subacute traumatic brain injury, helping the brain restore function to damaged cells.

The researchers cautioned that further animal studies will be required to discover the best dose and the best time window for optimal intranasal treatment.

###

Funding: National Institute of Neurological Disorders and Stroke RO1 NS062002 (YX), and National Institute on Aging RO1 AG037506 (MC).

Dwight Angell | Eurek Alert!
Further information:
http://www.henryford.com/

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>